KDOAM-25
Based on 9 publication(s) in Google Scholar
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2230731-99-2
- Formule: C15H25N5O2
- Masse moléculaire:307.39
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-15648B
GSK-J4JMJD3/UTX Inhibitor -
HY-12304
IOX12OG Oxygenases Inhibitor -
HY-13953
JIB-04Histone Demethylase Inhibitor -
HY-15648
GSK-J1JMJD3/KDM6B Inhibitor -
HY-12635
SP2509LSD1 Antagonist -
HY-139348
PFI-90KDM3B Inhibitor -
HY-18632
GSK2879552LSD1 Inhibitor -
HY-100421
CPI-455KDM5 Inhibitor -
HY-113039
L-2-Hydroxyglutaric acidEpigenetic Modifier -
HY-15648BR
GSK-J4 (Standard)JMJD3/UTX Inhibitor -
HY-12725
ML324JMJD2 Inhibitor -
HY-15648F
GSK-J4 hydrochlorideJMJD3/UTX Inhibitor
Publications Citing Use of MedChemExpress (MCE) KDOAM-25
More- Nat Cell Biol. 2024 Feb;26(2):263-277. [Abstract]
- Sci Adv. 2025 Jun 6;11(23):eadu2695. [Abstract]
- Clin Transl Med. 2024 Jun;14(6):e1692. [Abstract]
- Oncol Rep. 2026 Apr;55(4):79. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Cancer Res Commun. 2026 Mar 1;6(3):616-629. [Abstract]
- bioRxiv. 2024 October 03.
- Research Square Preprint. 2023 Dec 2.
- University of Gothenburg. 2023 Jun 27.
Activité biologique
Description
IC50 & Target
IC50: 71 nM (KDM5A), 19 nM (KDM5B), 69 nM (KDM5C), 69 nM (KDM5D)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MM1.S | EC50 |
>50 μM
Compound: 15
|
Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability
Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability
|
[PMID: 34555614] |
| MM1.S | IC50 |
30 μM
Compound: 11d
|
Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth
Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth
|
[PMID: 32883639] |
In Vitro
KDOAM-25 inhibits most potently KDM5B with an IC50 of ∼50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 shows no cellular activity on any of the other tested JmjC family members[1].
KDOAM-25 is able to reduce the viability of MM1S cells with an IC50 of ∼30 μM after a delay of 5-7 days[1].
KDOAM-25 treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase[1].
KDOAM-25 (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2230731-99-2
-
Masse moléculaire 307.39
-
Formule C15H25N5O2
-
SMILES
NC(C1=CC=NC(CNCC(N(CC)CCN(C)C)=O)=C1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
Single-cell multi-omics profiling of human preimplantation embryos identifies cytoskeletal defects during embryonic arrest. [Abstract]2024 Feb;26(2):263-277. PMID: 38238450 -
Sci Adv
Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform. [Abstract]2025 Jun 6;11(23):eadu2695. PMID: 40479052 -
Clin Transl Med
Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. [Abstract]2024 Jun;14(6):e1692. PMID: 38804602 -
Oncol Rep
2026 Apr;55(4):79. PMID: 41789643 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Cancer Res Commun
Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [Abstract]2026 Mar 1;6(3):616-629. PMID: 41747217 -
-
-
Protocole
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KDOAM-25 Related Classifications
HY-102047 Related Classifications
Powered by Bioz